Table 1.
Genotype frequencies of MYCN gene polymorphisms and neuroblastoma susceptibility
| Genotype | Cases (N=429) | Controls (N=884) | P-valuea | Crude OR (95% CI) | P-value | AOR (95% CI)b | P-valueb |
|---|---|---|---|---|---|---|---|
| rs57961569 G> A (HWE =0.379) | |||||||
| GG | 202 (47.09) | 372 (42.08) | 1.00 | 1.00 | |||
| GA | 171 (39.86) | 412 (46.61) | 0.76 (0.60–0.98) | 0.033 | 0.76 (0.60–0.98) | 0.033 | |
| AA | 56 (13.05) | 100 (11.31) | 1.03 (0.71–1.49) | 0.870 | 1.03 (0.71–1.50) | 0.862 | |
| Additive | 0.069 | 0.93 (0.78–1.11) | 0.411 | 0.93 (0.78–1.11) | 0.414 | ||
| Dominant | 227 (52.91) | 512 (57.92) | 0.086 | 0.82 (0.64–1.03) | 0.087 | 0.82 (0.65–1.03) | 0.087 |
| Recessive | 373 (86.95) | 784 (88.69) | 0.360 | 1.18 (0.83–1.67) | 0.361 | 1.18 (0.83–1.67) | 0.355 |
| rs9653226 T>C (HWE =0.569) | |||||||
| TT | 138 (32.17) | 293 (33.14) | 1.00 | 1.00 | |||
| TC | 202 (47.09) | 439 (49.66) | 0.98 (0.75–1.27) | 0.862 | 0.98 (0.75–1.27) | 0.850 | |
| CC | 89 (20.75) | 152 (17.19) | 1.24 (0.89–1.73) | 0.197 | 1.24 (0.89–1.73) | 0.201 | |
| Additive | 0.292 | 1.10 (0.93–1.29) | 0.272 | 1.10 (0.93–1.29) | 0.278 | ||
| Dominant | 291 (67.83) | 591 (66.86) | 0.724 | 1.05 (0.82–1.34) | 0.724 | 1.04 (0.82–1.34) | 0.736 |
| Recessive | 340 (79.25) | 732 (82.81) | 0.119 | 1.26 (0.94–1.69) | 0.119 | 1.26 (0.94–1.69) | 0.121 |
| rs13034994 A>G (HWE =0.907) | |||||||
| AA | 265 (61.77) | 526 (59.50) | 1.00 | 1.00 | |||
| AG | 134 (31.24) | 311 (35.18) | 0.86 (0.67–1.10) | 0.221 | 0.86 (0.67–1.10) | 0.225 | |
| GG | 30 (6.99) | 47 (5.32) | 1.27 (0.78–2.05) | 0.335 | 1.27 (0.79–2.06) | 0.329 | |
| Additive | 0.228 | 0.98 (0.81–1.19) | 0.868 | 0.99 (0.81–1.19) | 0.878 | ||
| Dominant | 164 (38.23) | 358 (40.50) | 0.431 | 0.91 (0.72–1.15) | 0.431 | 0.91 (0.72–1.15) | 0.437 |
| Recessive | 399 (93.01) | 837 (94.68) | 0.225 | 1.34 (0.83–2.15) | 0.227 | 1.34 (0.84–2.16) | 0.222 |
| rs60226897 G>A (HWE =0.526) | |||||||
| GG | 208 (48.48) | 410 (46.38) | 1.00 | 1.00 | |||
| GA | 174 (40.56) | 378 (42.76) | 0.91 (0.71–1.16) | 0.437 | 0.91 (0.71–1.16) | 0.442 | |
| AA | 47 (10.96) | 96 (10.86) | 0.97 (0.66–1.42) | 0.857 | 0.97 (0.66–1.43) | 0.871 | |
| Additive | 0.738 | 0.96 (0.80–1.14) | 0.610 | 0.96 (0.81–1.14) | 0.623 | ||
| Dominant | 221 (51.52) | 474 (53.62) | 0.474 | 0.92 (0.73–1.16) | 0.474 | 0.92 (0.73–1.16) | 0.482 |
| Recessive | 382 (89.04) | 788 (89.14) | 0.958 | 1.01 (0.70–1.46) | 0.958 | 1.01 (0.70–1.47) | 0.946 |
| Combined effect of risk genotypesc | |||||||
| 0 | 199 (46.39) | 428 (48.42) | 1.00 | 1.00 | |||
| 1 | 37 (8.62) | 107 (12.10) | 0.74 (0.49–1.12) | 0.157 | 0.74 (0.49–1.12) | 0.151 | |
| 2 | 87 (20.28) | 173 (19.57) | 1.08 (0.80–1.47) | 0.617 | 1.08 (0.80–1.47) | 0.620 | |
| 3 | 106 (24.71) | 176 (19.91) | 1.30 (0.97–1.74) | 0.084 | 1.29 (0.96–1.74) | 0.086 | |
| Trend | 0.086 | 1.09 (0.99–1.19) | 0.088 | 1.08 (0.99–1.19) | 0.090 | ||
| 0–1 | 236 (55.01) | 535 (60.52) | 1.00 | 1.00 | |||
| 2–3 | 193 (44.99) | 349 (39.48) | 0.057 | 1.25 (0.99–1.58) | 0.057 | 1.25 (0.99–1.58) | 0.058 |
Notes:
a
χ2 test for genotype distributions between neuroblastoma patients and controls.
b
Adjusted for age and gender.
c
Risk genotypes were rs57961569 GG, rs9653226 CC, rs13034994 GG, and rs60226897 GG. Bold figures indicate 95% CI excluded 1 or P<0.05.
Abbreviations: AOR, adjusted odds ratio; CI, confidence interval; HWE, Hardy–Weinberg equilibrium; OR, odds ratio.